Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF (NCT05389215)

🧪 Interventions in This Study

• DWN12088 (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (30 Sites)

Showing the first 25 of 30 sites.

• Pulmonary Associates, PA — Mesa, Arizona
• Dignity Health Norton Thoracic Institute — Phoenix, Arizona
• The University of California San Francisco — San Francisco, California
• Loyola University Medical Center (LUMC) — Maywood, Illinois
• University of Kansas Medical Center Research Institute, Inc — Kansas City, Kansas
• Tufts Medical Center — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• University of Michigan Health System — Michigan Center, Michigan
• The Lung Research Center, LLC — Chesterfield, Missouri
• Duke University Medical Center — Durham, North Carolina
• Pulmonix Research, LLC — Greensboro, North Carolina
• Legacy Research Institute — Portland, Oregon
• Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
• The U.S. Department of Veterans Affairs — Charleston, South Carolina
• Lowcountry Lung and Critical Care — Charleston, South Carolina
• Baylor Scott & White Research Institute — Dallas, Texas
• The University of Texas Southwestern Medical Center — Dallas, Texas
• Baylor College of Medicine — Houston, Texas
• The University of Texas Health San Antonio Medical Arts & Research Center — San Antonio, Texas
• Inje University Busan Paik Hospital — Busan, Busan
• The Catholic University of Korea, Bucheon St. Mary's Hospital — Bucheon-si, Gyeonggi-do
• Myongji Hospital — Goyang-si, Gyeonggi-do
• Soon Chun Hyang University Hospital Bucheon — Bucheon-si, Gyeonggido
• Ajou University Hospital — Hwaseong-si, Gyeonggido

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Idiopathic Pulmonary Fibrosis

• Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
• A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
• LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
• Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
• MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales

Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.